Diligence memo · auto-generated · as of July 2, 2026
LP Investors, LLC
LP Investors, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
LP Investors, LLC operates in Pharmaceuticals, based in FAIRFIELD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
LP Investors, LLC has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $40M on 2017-12-28.
Most recent recorded round closed around 2017-12-28.
Valuation (modeled)modeled
Provath models LP Investors, LLC at approximately $1.4B (range $84M–$5.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.00× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 8.5 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co, X4 Pharmaceuticals, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.